Core Insights - CooperCompanies reported solid financial results for the fiscal second quarter ended April 30, 2025, with a total revenue increase of 6% year-over-year to 1,002.3million,drivenbygrowthinbothCooperVisionandCooperSurgicalsegments[5][6][42]−Thecompanyemphasizeditsfocusonmarketshareexpansion,productlaunches,andcapacityexpansionprojectsmovingforward[2]FinancialPerformance−CooperVision(CVI)revenueincreasedby5669.6 million, with organic growth of 7% [5][42] - CooperSurgical (CSI) revenue rose by 8% year-over-year to 332.7million,withorganicgrowthof70.96, while GAAP diluted EPS remained consistent at 0.44[5][40]RevenueBreakdown−Totalrevenueof1,002.3 million consisted of CooperVision's 669.6millionandCooperSurgical′s332.7 million [5][42] - Revenue by geography showed the Americas at 282.4million(up7248.6 million (up 5%), and Asia Pacific at 138.6million(up318.1 million after capital expenditures of 78.1million[6][8]−Interestexpensedecreasedto24.2 million from 28.9millionduetolowerinterestratesandreducedaveragedebt[6][40]ShareRepurchaseProgram−Duringthesecondquarter,CooperCompaniesrepurchased40.6 million of common stock, approximately 537.2 thousand shares, at an average price of 75.60[8]FiscalYear2025Guidance−Thecompanyupdateditsfiscalyear2025financialguidance,projectingtotalrevenuebetween4,107 million and $4,146 million, with organic growth of 5% to 6% [14]